Zegerid Study Shows Benefits For Immediate-Release PPI/Antacid
This article was originally published in The Tan Sheet
Executive Summary
Santarus announces positive clinical trial results for its prescription Zegerid proton pump inhibitor/antacid as it pursues an OTC switch application for a lower-dose version of the combination product
You may also be interested in...
Zegerid Switch Progress Generates Bottom Line Help For Santarus
Santarus' OTC licensing of its Zegerid Rx heartburn remedy to Schering-Plough has yet to pay dividends for S-P, but the deal is already helping Santarus reduce its net loss
Zegerid Switch Progress Generates Bottom Line Help For Santarus
Santarus' OTC licensing of its Zegerid Rx heartburn remedy to Schering-Plough has yet to pay dividends for S-P, but the deal is already helping Santarus reduce its net loss
Zegerid Switch Progress Generates Bottom Line Help For Santarus
Santarus' OTC licensing of its Zegerid Rx heartburn remedy to Schering-Plough has yet to pay dividends for S-P, but the deal is already helping Santarus reduce its net loss